Nexalin Technology, Inc. Share Price

Equities

NXL

US65345B2016

Advanced Medical Equipment & Technology

Delayed Nasdaq 11:20:12 13/05/2024 pm IST 5-day change 1st Jan Change
1.22 USD -4.69% Intraday chart for Nexalin Technology, Inc. -11.59% +201.38%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
Sales 2022 1.32M 110M Sales 2023 111K 9.24M Capitalization 3.01M 251M
Net income 2022 -1M -83.46M Net income 2023 -4M -334M EV / Sales 2022 -0.59 x
Net cash position 2022 6.24M 521M Net cash position 2023 2.94M 246M EV / Sales 2023 0.6 x
P/E ratio 2022
-2.46 x
P/E ratio 2023
-0.64 x
Employees 6
Yield 2022 *
-
Yield 2023
-
Free-Float 77.08%
More Fundamentals * Assessed data
Dynamic Chart
Nexalin Technology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Nexalin Technology Regains Compliance With Nasdaq Listing Requirement MT
Nexalin Technology Files $5.6 Million Shelf Registration MT
Nexalin Technology Accelerates Manufacturing of Its HALO? Clarity Following Successful Usability, Feasibility, and Electrical Testing CI
Nexalin Technology, Inc. Announces the Appointment of William A. Hudson, Jr. to Military & Government Advisory Board CI
Top Midday Gainers MT
Nexalin Technology, Inc. Announces Positive Results of Clinical Study Validating its Gen-2 TACS Device for Reducing Pain Among Veterans with Mild Traumatic Brain Injury at University of California, San Diego CI
Nexalin Technology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Nexalin Technology, Inc. Commences Sales of Gen-2 Neurostimulation Device to New Mental Health Center in Oman CI
Nexalin Technology, Inc. Announces Positive Results from Clinical Study of Its Gen-2 Tacs Device for Treating Adult Patients with Chronic Insomnia CI
Nexalin Technology Announces Regulatory Approval in Oman for Gen-2 Neurostimulation Device CI
Nexalin Technology, Inc. Unveils Gen-3 HALO?? Clarity 15 Milliamp Neurostimulation Device CI
Nexalin Technology, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Nexalin Technology, Inc. Announces Publication of Deep-Brain Stimulation Study in Leading Peer-Reviewed Journal CI
Nexalin Technology, Inc. Announces Resignation of Marilyn Elson as Chief Financial Officer CI
More news
1 day-4.69%
1 week-11.59%
Current month-20.26%
1 month-38.38%
3 months+293.42%
6 months+258.82%
Current year+201.38%
More quotes
1 week
1.14
Extreme 1.14
1.43
1 month
0.79
Extreme 0.791
2.46
Current year
0.25
Extreme 0.2528
3.40
1 year
0.25
Extreme 0.2528
3.40
3 years
0.25
Extreme 0.2528
3.40
5 years
0.25
Extreme 0.2528
3.40
10 years
0.25
Extreme 0.2528
3.40
More quotes
Managers TitleAgeSince
Founder - 19/10/19
Chief Executive Officer 62 01/18/01
Chief Tech/Sci/R&D Officer 63 01/17/01
Members of the board TitleAgeSince
Chairman 80 -
Chief Executive Officer 62 01/18/01
Director/Board Member 63 01/19/01
More insiders
Date Price Change Volume
13/24/13 1.22 -4.69% 27 024
10/24/10 1.28 +10.34% 66,030
09/24/09 1.16 -4.13% 31,622
08/24/08 1.21 -6.92% 41,031
07/24/07 1.3 -5.80% 36,062

Delayed Quote Nasdaq, May 13, 2024 at 11:20 pm IST

More quotes
Nexalin Technology, Inc. is engaged in designing and developing neurostimulation products for the mental health epidemic. The Company has developed an easy-to-administer medical device (Generation 1 or Gen-1) that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit a waveform at 4 milliamps during treatment. It also has designed and developed a new advanced waveform technology to be emitted at 15 milliamps through new and improved medical devices referred to as (Generation 2 or Gen-2) and (Generation 3 or Gen-3). Gen-2 is a clinical use device with a modern enclosure to emit the new 15 milliamp advanced waveform. Gen-3 is a new patient headset that will be prescribed by licensed medical professionals in a virtual clinic setting like existing telehealth platforms. Its products are non-invasive and undetectable to the human body.
Calendar
More about the company
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW